|
1
|
Mohan M, Kumar M, Samant R, Van Hemert R
Jr, Tian E, Desai S, van Rhee F, Thanendrarajan S, Schinke C, Suva
LJ, et al: Bone remineralization of lytic lesions in multiple
myeloma-the Arkansas experience. Bone. 146(115876)2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Martino A, Buda G, Maggini V, Lapi F,
Lupia A, Di Bello D, Orciuolo E, Galimberti S, Barale R, Petrini M
and Rossi AM: Could age modify the effect of genetic variants in
IL6 and TNF-α genes in multiple myeloma? Leuk Res. 36:594–597.
2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Clay-Gilmour AI, Hildebrandt MAT, Brown
EE, Hofmann JN, Spinelli JJ, Giles GG, Cozen W, Bhatti P, Wu X,
Waller RG, et al: Coinherited genetics of multiple myeloma and its
precursor, monoclonal gammopathy of undetermined significance.
Blood Adv. 4:2789–2797. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Gaudio A, Xourafa A, Rapisarda R, Zanoli
L, Signorelli SS and Castellino P: Hematological diseases and
osteoporosis. Int J Mol Sci. 21(3538)2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Auzina D, Erts R and Lejniece S:
Prognostic value of the bone turnover markers in multiple myeloma.
Exp Oncol. 39:53–56. 2017.PubMed/NCBI
|
|
6
|
Terpos E, Christoulas D and Gavriatopoulou
M: Biology and treatment of myeloma related bone disease.
Metabolism. 80:80–90. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Łacina P, Butrym A, Humiński M, Dratwa M,
Frontkiewicz D, Mazur G and Bogunia-Kubik K: Association of RANK
and RANKL gene polymorphism with survival and calcium levels in
multiple myeloma. Mol Carcinog. 60:106–112. 2021.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Westhrin M, Kovcic V, Zhang Z, Moen SH,
Nedal TMV, Bondt A, Holst S, Misund K, Buene G, Sundan A, et al:
Monoclonal immunoglobulins promote bone loss in multiple myeloma.
Blood. 136:2656–2666. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tanimoto K, Hiasa M, Tenshin H, Teramachi
J, Oda A, Harada T, Ashtar M, Sogabe K, Oura M, Endo I, et al:
Mechanical unloading enhances bone destruction and tumor expansion
in multiple myeloma: Critical roles of osteocytic RANKL induction.
Bone Rep. 13(100425)2020.
|
|
10
|
Annibali O, Petrucci MT, Santini D,
Bongarzoni V, Russano M, Pisani F, Venditti O, Pantano F, Rago A,
Siniscalchi A, et al: Alkaline phosphatase (ALP) levels in multiple
myeloma and solid cancers with bone lesions: Is there any
difference? J Bone Oncol. 26(100338)2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Diaz-delCastillo M, Chantry AD, Lawson MA
and Heegaard AM: Multiple myeloma-a painful disease of the bone
marrow. Semin Cell Dev Biol. 12:49–58. 2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Gu J, Huang X, Zhang Y, Bao C, Zhou Z and
Jin J: Cytokine profiles in patients with newly diagnosed multiple
myeloma: Survival is associated with IL-6 and IL-17A levels.
Cytokine. 138(155358)2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Toscani D, Bolzoni M, Ferretti M, Palumbo
C and Giuliani N: Role of osteocytes in myeloma bone disease:
Anti-sclerostin antibody as new therapeutic strategy. Front
Immunol. 9(2467)2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Çetin G, Eşkazan AE, Ar MC, Aydın ŞÖ,
Ferhanoğlu B, Soysal T, Başlar Z and Aydın Y: Bone-specific
alkaline phosphatase levels among patients with multiple myeloma
receiving various therapy options. Turk J Haematol. 31:374–380.
2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Nizet A, Cavalier E, Stenvinkel P,
Haarhaus M and Magnusson P: Bone alkaline phosphatase: An important
biomarker in chronic kidney disease-mineral and bone disorder. Clin
Chim Acta. 501:198–206. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Jasrotia S, Gupta R, Sharma A, Halder A
and Kumar L: Cytokine profile in multiple myeloma. Cytokine.
136(155271)2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Burger R, Günther A, Klausz K, Staudinger
M, Peipp M, Penas EM, Rose-John S, Wijdenes J and Gramatzki M: Due
to interleukin-6 type cytokine redundancy only glycoprotein 130
receptor blockade efficiently inhibits myeloma growth.
Haematologica. 102:381–390. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Vainer N, Dehlendorff C and Johansen JS:
Systematic literature review of IL-6 as a biomarker or treatment
target in patients with gastric, bile duct, pancreatic and
colorectal cancer. Oncotarget. 9:29820–29841. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Trigo FM, Luizon MR, Dutra HS, Maiolino A,
Nucci M and Simões BP: Interaction between IL-6 and TNF-α genotypes
associated with bacteremia in multiple myeloma patients submitted
to autologous stem cell transplantation (ASCT). Leuk Res Rep.
3:76–78. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wu XY, Tian F, Su MH, Wu M, Huang Y, Hu
LH, Jin L and Zhu XJ: BF211, a derivative of bufalin, enhances the
cytocidal effects in multiple myeloma cells by inhibiting the
IL-6/JAK2/STAT3 pathway. Int Immunopharmacol. 64:24–32.
2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Matthes T, Manfroi B and Huard B:
Revisiting IL-6 antagonism in multiple myeloma. Crit Rev Oncol
Hematol. 105:1–4. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ameri Z, Ghiasi S, Farsinejad A,
Hassanshahi G, Ehsan M and Fatemi A: Telomerase inhibitor MST-312
induces apoptosis of multiple myeloma cells and down-regulation of
anti-apoptotic, proliferative and inflammatory genes. Life Sci.
228:66–71. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Harmer D, Falank C and Reagan MR:
Interleukin-6 interweaves the bone marrow microenvironment, bone
loss, and multiple myeloma. Front Endocrinol (Lausanne).
9(788)2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Mahdavi Sharif P, Jabbari P, Razi S,
Keshavarz-Fathi M and Rezaei N: Importance of TNF-alpha and its
alterations in the development of cancers. Cytokine.
130(155066)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Lemancewicz D, Bolkun L, Jablonska E,
Kulczynska A, Bolkun-Skornicka U, Kloczko J and Dzieciol J:
Evaluation of TNF superfamily molecules in multiple myeloma
patients: Correlation with biological and clinical features. Leuk
Res. 37:1089–1093. 2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kovacs-Benke E: Monitoring disease status
in multiple myeloma in view of proliferation-leading cytokines.
Cancer Immunol Res. 2(1010)2017.
|
|
27
|
Li A, Sun K, Wang J, Wang S, Zhao X, Liu R
and Lu Y: Recombinant expression, purification and characterization
of human soluble tumor necrosis factor receptor 2. Protein Expr
Purif. 182(105857)2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hong Y, Yu J, Wang G and Qiao W:
Association between tumor necrosis factor alpha gene polymorphisms
and multiple myeloma risk: An updated meta-analysis. Hematology.
24:216–224. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
D'Souza C, Prince H and Neeson P:
Understanding the role of T-cells in the antimyeloma effect of
immunomodulatory drugs. Front Immunol. 12(632399)2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Børset M, Sundan A, Waage A and Standal T:
Why do myeloma patients have bone disease? A historical
perspective. Blood Rev. 41(100646)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kleber M, Ntanasis-Stathopoulos I,
Dimopoulos MA and Terpos E: Monoclonal antibodies against RANKL and
sclerostin for myeloma-related bone disease: Can they change the
standard of care? Expert Rev Hematol. 12:651–663. 2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Marino S and Roodman GD: Multiple myeloma
and bone: The fatal interaction. Cold Spring Harb Perspect Med.
8(a031286)2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Abramson HN: Monoclonal antibodies for the
treatment of multiple myeloma: An update. Int J Mol Sci.
19(3924)2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Terpos E, Raje N, Croucher P, Garcia-Sanz
R, Leleu X, Pasteiner W, Wang Y, Glennane A, Canon J and Pawlyn C:
Denosumab compared with zoledronic acid on PFS in multiple myeloma:
Exploratory results of an international phase 3 study. Blood Adv.
5:725–736. 2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Terpos E, Ntanasis-Stathopoulos I and
Dimopoulos M: Myeloma bone disease: From biology findings to
treatment approaches. Blood. 133:1534–1539. 2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Chubb SAP and Vasikaran SD: Measurement
and clinical utility of βCTX in serum and plasma. Adv Clin Chem.
81:97–134. 2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Shetty S, Kapoor N, Bondu JD, Thomas N and
Paul TV: Bone turnover markers: Emerging tool in the management of
osteoporosis. Indian J Endocrinol Metab. 20:846–852.
2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Ting KR, Brady JJ, Hameed A, Le G, Meiller
J, Verburgh E, Bayers C, Benjamin D, Anderson KC, Richardson PG, et
al: Clinical utility of C-terminal telopeptide of type 1 collagen
in multiple myeloma. Br J Haematol. 173:82–88. 2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Lorentzon M, Branco J, Brandi ML, Bruyère
O, Chapurlat R, Cooper C, Cortet B, Diez-Perez A, Ferrari S,
Gasparik A, et al: Algorithm for the use of biochemical markers of
bone turnover in the diagnosis, assessment and follow-up of
treatment for osteoporosis. Adv Ther. 36:2811–2824. 2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Vallet S, Hoyle NR, Kyle RA, Podar K and
Pecherstorfer M: A role for bone turnover markers β-CrossLaps (CTX)
and amino-terminal propeptide of type I collagen (PINP) as
potential indicators for disease progression from MGUS to multiple
myeloma. Leuk Lymphoma. 59:2431–2438. 2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Tian A, Ma J, Feng K, Liu Z, Chen L, Jia H
and Ma X: Reference markers of bone turnover for prediction of
fracture: A meta-analysis. J Orthop Surg Res. 14(68)2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Terpos E, Dimopoulos MA, Sezer O, Roodman
D, Abildgaard N, Vescio R, Tosi P, Garcia-Sanz R, Davies F,
Chanan-Khan A, et al: The use of biochemical markers of bone
remodeling in multiple myeloma: A report of the international
myeloma working group. Leukemia. 24:1700–1712. 2010.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Raje N, Bhatta S and Terpos E: Role of the
RANK/RANKL pathway in multiple myeloma. Clin Cancer Res. 25:12–20.
2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Maaroufi A, Khadem-Ansari MH, Khalkhali HR
and Rasmi Y: Serum levels of bone sialoprotein, osteopontin, and
β2-microglobulin in stage I of multiple myeloma. J Cancer Res Ther.
16:98–101. 2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Terpos E: Biochemical markers of bone
metabolism in multiple myeloma. Cancer Treat Rev. 32 (Suppl
1):S15–S19. 2006.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Zhou F, Meng S, Song H and Claret FX:
Dickkopf-1 is a key regulator of myeloma bone disease:
Opportunities and challenges for therapeutic intervention. Blood
Rev. 27:261–267. 2013.PubMed/NCBI View Article : Google Scholar
|
